Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Ars Pharmaceuticals, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

Not required for a “smaller reporting company” as defined under Item 10(f)(1) of Regulation S-K of the Securities Act.